Rituximab Therapy for Recalcitrant Idiopathic Sclerosing Orbital Inflammation

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Idiopathic sclerosing orbital inflammation is a rare, debilitating condition.
• Recalcitrant cases often fail to respond to conventional immunotherapy and surgery.
• Optic neuropathy is a potential severe complication.

Purpose of the Study:

• To evaluate the efficacy of rituximab in treating refractory idiopathic sclerosing orbital inflammation.
• To assess the response of different lesion types (localized vs. diffuse) to rituximab therapy.
• To determine the long-term outcomes and potential for recurrence.

Main Methods:

• Retrospective analysis of three female patients with idiopathic sclerosing orbital inflammation.
• Treatment with rituximab (375 mg/m2/week for 4 weeks).
• Clinical and radiological assessment of treatment response and follow-up evaluations.

Main Results:

• All patients showed symptomatic improvement after rituximab infusions.
• Complete radiological resolution of local lesions and partial resolution of diffuse lesions.
• Two patients experienced recurrent inflammation but responded well to short-term steroid treatment.

Conclusions:

• Short-term rituximab therapy can induce effective remission in refractory idiopathic sclerosing orbital inflammation.
• Early and localized lesions may respond better than diffuse lesions.
• Inflammatory exacerbations can occur, necessitating ongoing monitoring and management.